Table 5.
Published evidence of second-line systemic therapy in rhabdomyosarcoma.
| Regimen | Type of Study | N | Setting | RR | PFS (Months) | Toxicity | Ref |
|---|---|---|---|---|---|---|---|
| Vinorelbine | Phase II | 33 (13 RMS) | Pediatric sarcoma patients | 50% | 3.5 (all the series) | 63% G3-4 neutropenia | [29] |
| Vinorelbine-Cyclophosphamide | Phase II | 117 (50 RMS) | Pediatric and <25 and adults relapsed tumors | 36% | NR | 38% G3-4 neutropenia | [26] |
| Cyclophosphamide-Topotecan | Retrospective | 15 (6 RMS) | Adult relapsed sarcoma patients | 33% (2/6) | 2.5 (all the series) | 47% hematologic toxicity | [30] |
| Cyclophosphamide-Topotecan | Phase II window trial | 61 | Pediatric metastatic RMS (1st line) | 47% | NR (3-y DFS: 10%) | G3-4: leucopenia 52%, anemia 37% | [31] |
| Cyclophosphamide-Topotecan | Phase II | 91 (15 RMS) | Pediatric relapsed tumors | 66% (10/15 RMS) | NR | G3-4: leucopenia 53%, anemia 27% | [32] |
| Vincristine-Irinotecan | Phase II window trial (2 regimens) | 92 | Pediatric relapsed RMS | 26–37% | NR (1y-FFS 37 and 38%) | ≥G3: 50–66% | [33] |
| Vincristine-temozolomide-irinotecan | Retrospective | 19 | Pediatric relapsed RMS | 0 | PFS-3 months: 23% | NR | [34] |
| Topotecan-carboplatin | Phase II | 38 | Pediatric relapsed RMS | 28% | 5-y PFS 14% | 63% G4 hematologic | [13] |
| Cisplatin-etoposide | Phase II | 27 (21 RMS) | Pediatric relapsed tumors | 33% (7/21) | NR | NR | [12] |
| Ifosfamide-carboplatin-etoposide (ICE) | Phase I and II trials analysis | 97 (27 RMS) | Pediatric and adolescent relapse sarcoma | 66% (RMS) | NR | G3-4 hematologic: 100% | [36] |
| Vincristine, ifosfamide and doxorubicin (VIA)/etoposide, ifosfamide and cisplatin (VIP) | Retrospective | 6 | Adult patients (advance disease) | 100% | NR | NR | [28] |
| Several regimenes | Retrospective | 49 | Pediatric relapsed RMS | NR | NR | [10] | |
| Carboplatin-epirubicin- vincristine ad ifosfamide-vincristine- etoposide (CEV/IVE) |
15 | 73.3% | |||||
| Vincristine/irinotecan ± temozolomide (VI[T]) | 7 | 42.9% | |||||
| Gemcitabine-docetaxel | Retrospective | 19 (5 RMS) | Pediatric relapsed sarcoma | 40% (2/5) | 2 (all series) | G3-4 toxicity 74% | [35] |
RR: response rate; PFS: progression-free survival; NR: not reported; DFS: disease-free survival; FFS: failure-free survival; RMS: rhabdomyosarcoma.